KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer Last updated on Apr 21, 2024 Previous CALLA: Durvalumab versus placebo with chemoradiotherapy Next Publications Update # 51